share_log
Reuters ·  Apr 29 06:30
X4 Pharmaceuticals Announces FDA Approval of Xolremdi™ (Mavorixafor) Capsules, First Drug Indicated in Patients With Whim Syndrome
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment